CTOs on the Move

Aduro Biotech

www.aduro.com

 
Aduro Biotech, Inc. is an immunotherapy company focused on the discovery, development and commercialization of therapies that transform the treatment of challenging diseases. Aduro`s technology platforms, which are designed to harness the body`s natural immune system, are being investigated in cancer indications and have the potential to expand into autoimmune and infectious diseases. Aduro`s LADD technology platform is based on proprietary attenuated strains of Listeria that have been engineered to express tumor-associated antigens to induce specific and targeted immune responses. Based on compelling clinical data in advanced cancers, this platform is being developed as a treatment for multiple indications, including ...
  • Number of Employees: 100-250
  • Annual Revenue: $0-1 Million
  • www.aduro.com
  • 626 Bancroft Way #3C
    Berkeley, CA USA 94710
  • Phone: 510.848.4400

Executives

Name Title Contact Details

Similar Companies

GeneGo bioinformatics software

GeneGo bioinformatics software is a Saint Joseph, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

64x Bio

64x Bio is transforming the future of cell and gene therapy manufacturing with high throughput discovery and design of enhanced cell lines for next-generation biomanufacturing and therapeutics.

Dendreon

Dendreon is a biotechnology company with a singular mission: to harness the power of the body`s immune system to safely improve and extend the lives of people battling cancer. Dendreon`s PROVENGE® (sipuleucel-T), which was approved by the U.S. Food and Drug Administration in April 2010, is the only cellular immunotherapy cancer treatment available. Dendreon is working to expand the application of its technology to discover, develop, manufacture and market additional product candidates for a variety of cancers in the future. Dendreon headquarters are in in Seal Beach, California.

Neuros Medical

Neuros Medical, a Cleveland, Ohio based neurostimulation company, is focused on developing proprietary neurostimulation therapies for unmet needs to patients worldwide.